Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fibrosis of Liver Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 27, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

NCT03654053
View directory record Official record
Conditions
Cirrhosis
Interventions
Placebo Oral Tablet, Simvastatin 40mg
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
San Francisco, California • West Haven, Connecticut • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 27, 2026, 3:33 AM EDT
Terminated Not applicable Interventional

Selenium Supplementation of Patients With Cirrhosis

NCT00271245
View directory record Official record
Conditions
Liver Disease
Interventions
200 µg selenium as selenate, 400 µg selenium as selenate, 200 µg selenium as selenomethionine, Placebo
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 27, 2026, 3:33 AM EDT
Not listed Phase 2 Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

NCT00281502
View directory record Official record
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Early Phase 1 Interventional

Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis

NCT03407001
View directory record Official record
Conditions
Cirrhosis
Interventions
Contrast-Enhanced Ultrasound, Sulfur Hexafluoride Lipid Microspheres, Ultrasound
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 27, 2026, 3:33 AM EDT
Terminated No phase listed Observational

Biomarkers of Liver Fibrosis

NCT02438917
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

NCT02138253
View directory record Official record
Conditions
Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Coronado, California • La Jolla, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

NCT00406237
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
tigecycline
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Saint Paul, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Sep 27, 2026, 3:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

NCT05692024
View directory record Official record
Conditions
Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis, Fibrosis, Liver, Ultrasound Elastography, Proton Magnetic Resonance Spectroscopy
Interventions
Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule., Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Recruiting Phase 1 Interventional

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559
View directory record Official record
Conditions
Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

NCT02230683
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cirrhosis, Portal Hypertension
Interventions
IDN-6556
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
West Haven, Connecticut • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 27, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196, Placebo, Liver Biopsy
Drug · Procedure
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
90
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

EGCG for Hepatocellular Carcinoma Chemoprevention

NCT06015022
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Epigallocatechin gallate (EGCG), Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

NCT06525311
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis
Interventions
K-808
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Coronado, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 27, 2026, 3:33 AM EDT
Terminated Phase 3 Interventional Results available

To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

NCT06488911
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Coronado, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

NCT02201901
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 27, 2026, 3:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

NCT07042919
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Zanzalintinib
Procedure · Drug
Lead sponsor
Devalingam Mahalingam
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05395481
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions
LY3849891, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Orange, California • Rialto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

NCT04814602
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Proglumide
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 27, 2026, 3:33 AM EDT
Recruiting Phase 3 Interventional

Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

NCT07424677
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lakewood Rch, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

NCT01707472
View directory record Official record
Conditions
Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
Interventions
Simtuzumab
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 27, 2026, 3:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

NCT06715670
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Zibotentan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 27, 2026, 3:33 AM EDT
Terminated Phase 4 Interventional

Sodium Restriction in the Management of Cirrhotic Ascites

NCT00548366
View directory record Official record
Conditions
Ascites
Interventions
Sodium restriction
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 27, 2026, 3:33 AM EDT